PMID- 28603426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 10
DP  - 2017
TI  - Efficacy and safety of TACE in combination with sorafenib for the treatment of 
      TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a 
      retrospective study.
PG  - 2761-2768
LID - 10.2147/OTT.S131022 [doi]
AB  - BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib (SOR) are 
      well-established treatments for hepatocellular carcinoma (HCC). This study 
      evaluates the efficacy and safety of SOR combined with TACE in the treatment of 
      patients with TACE-refractory, advanced-stage HCC. METHODS: This retrospective 
      study included 61 patients with TACE-refractory advanced HCC. Patients were 
      divided into TACE + SOR (n=30) and TACE (n=31) treatment groups. Patient 
      demographic and clinical characteristics, overall survival (OS), time to 
      progression (TTP), disease control rate (DCR), and adverse events (AEs) were 
      compared between the two groups. RESULTS: Compared with TACE alone, the 5-year OS 
      and TTP were prolonged in the TACE + SOR group (median OS: 17.9 vs 7.1 months, 
      P<0.001; median TTP: 9.3 vs 3.4 months, P<0.001). Multivariate analysis showed 
      that Child-Pugh class A (hazard ratio [HR], 0.234; 95% confidence interval [CI], 
      0.092-0.595), Eastern Cooperative Oncology Group performance status 1 (HR, 0.355; 
      95% CI, 0.153-0.826), alpha-fetoprotein <400 ng/mL (HR, 0.349; 95% CI, 
      0.177-0.689), and TACE + SOR treatment (HR, 0.151; 95% CI, 0.071-0.322) were 
      independent, positive predictive factors of OS. CONCLUSION: The OS and TTP in the 
      combined treatment group were significantly improved when compared with the TACE 
      group. However, no significant difference in DCR was found between these two 
      groups. While no AEs occurred in the TACE group, two patients in the TACE + SOR 
      group experienced severe AEs which were effectively mitigated by lowering the 
      dose of SOR. Thus, SOR in combination with TACE is a safe and effective treatment 
      for advanced-stage, prior-TACE-resistant HCC.
FAU - Wu, Jianbing
AU  - Wu J
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Li, An
AU  - Li A
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Yang, Jiajin
AU  - Yang J
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Lu, Yanjun
AU  - Lu Y
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
FAU - Li, Jie
AU  - Li J
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170529
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5457121
OTO - NOTNLM
OT  - TACE-refractory
OT  - adverse events
OT  - hepatocellular carcinoma
OT  - overall survival
OT  - sorafenib
OT  - time to progression
OT  - transarterial chemoembolization
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/06/13 06:00
MHDA- 2017/06/13 06:01
PMCR- 2017/05/29
CRDT- 2017/06/13 06:00
PHST- 2017/06/13 06:00 [entrez]
PHST- 2017/06/13 06:00 [pubmed]
PHST- 2017/06/13 06:01 [medline]
PHST- 2017/05/29 00:00 [pmc-release]
AID - ott-10-2761 [pii]
AID - 10.2147/OTT.S131022 [doi]
PST - epublish
SO  - Onco Targets Ther. 2017 May 29;10:2761-2768. doi: 10.2147/OTT.S131022. 
      eCollection 2017.